75 related articles for article (PubMed ID: 21316841)
21. Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer.
Kosaka T; Miyajima A; Shirotake S; Kikuchi E; Hasegawa M; Mikami S; Oya M
Prostate; 2010 Feb; 70(2):162-9. PubMed ID: 19760626
[TBL] [Abstract][Full Text] [Related]
22. Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221.
Creighton-Gutteridge M; Cardellina JH; Stephen AG; Rapisarda A; Uranchimeg B; Hite K; Denny WA; Shoemaker RH; Melillo G
Clin Cancer Res; 2007 Feb; 13(3):1010-8. PubMed ID: 17289897
[TBL] [Abstract][Full Text] [Related]
23. Effects of geldanamycin on HIF-1alpha mediated angiogenesis and invasion in prostate cancer cells.
Alqawi O; Moghaddas M; Singh G
Prostate Cancer Prostatic Dis; 2006; 9(2):126-35. PubMed ID: 16432534
[TBL] [Abstract][Full Text] [Related]
24. Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells.
Merighi S; Benini A; Mirandola P; Gessi S; Varani K; Simioni C; Leung E; Maclennan S; Baraldi PG; Borea PA
Mol Pharmacol; 2007 Aug; 72(2):395-406. PubMed ID: 17488804
[TBL] [Abstract][Full Text] [Related]
25. Effects of transferrin receptor blockade on cancer cell proliferation and hypoxia-inducible factor function and their differential regulation by ascorbate.
Jones DT; Trowbridge IS; Harris AL
Cancer Res; 2006 Mar; 66(5):2749-56. PubMed ID: 16510596
[TBL] [Abstract][Full Text] [Related]
26. Hepatocyte growth factor-activated NF-kappaB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines.
Tacchini L; De Ponti C; Matteucci E; Follis R; Desiderio MA
Carcinogenesis; 2004 Nov; 25(11):2089-100. PubMed ID: 15240510
[TBL] [Abstract][Full Text] [Related]
27. Over-expression of hypoxia-inducible factor-1alpha increases the invasive potency of LNCaP cells in vitro.
Luo Y; He DL; Ning L; Shen SL; Li L; Li X; Zhau HE; Chung LW
BJU Int; 2006 Dec; 98(6):1315-9. PubMed ID: 16956360
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.
Generali D; Berruti A; Brizzi MP; Campo L; Bonardi S; Wigfield S; Bersiga A; Allevi G; Milani M; Aguggini S; Gandolfi V; Dogliotti L; Bottini A; Harris AL; Fox SB
Clin Cancer Res; 2006 Aug; 12(15):4562-8. PubMed ID: 16899602
[TBL] [Abstract][Full Text] [Related]
29. Erythropoietin disrupts hypoxia-inducible factor signaling in ovarian cancer cells.
Hale SA; Wong C; Lounsbury KM
Gynecol Oncol; 2006 Jan; 100(1):14-9. PubMed ID: 16226302
[TBL] [Abstract][Full Text] [Related]
30. Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer.
Baker AF; Koh MY; Williams RR; James B; Wang H; Tate WR; Gallegos A; Von Hoff DD; Han H; Powis G
Pancreas; 2008 Mar; 36(2):178-86. PubMed ID: 18376310
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer.
Schoppmann SF; Fenzl A; Schindl M; Bachleitner-Hofmann T; Nagy K; Gnant M; Horvat R; Jakesz R; Birner P
Breast Cancer Res Treat; 2006 Sep; 99(2):135-41. PubMed ID: 16555123
[TBL] [Abstract][Full Text] [Related]
32. Inhibitor of DNA binding 1 activates vascular endothelial growth factor through enhancing the stability and activity of hypoxia-inducible factor-1alpha.
Kim HJ; Chung H; Yoo YG; Kim H; Lee JY; Lee MO; Kong G
Mol Cancer Res; 2007 Apr; 5(4):321-9. PubMed ID: 17426247
[TBL] [Abstract][Full Text] [Related]
33. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer.
Yamamoto Y; Ibusuki M; Okumura Y; Kawasoe T; Kai K; Iyama K; Iwase H
Breast Cancer Res Treat; 2008 Aug; 110(3):465-75. PubMed ID: 17805961
[TBL] [Abstract][Full Text] [Related]
34. Opposite functions of HIF-α isoforms in VEGF induction by TGF-β1 under non-hypoxic conditions.
Chae KS; Kang MJ; Lee JH; Ryu BK; Lee MG; Her NG; Ha TK; Han J; Kim YK; Chi SG
Oncogene; 2011 Mar; 30(10):1213-28. PubMed ID: 21057546
[TBL] [Abstract][Full Text] [Related]
35. Melittin inhibits the expression of key genes involved in tumor microenvironment formation by suppressing HIF-1α signaling in breast cancer cells.
Mir Hassani Z; Nabiuni M; Parivar K; Abdirad S; Karimzadeh L
Med Oncol; 2021 Jun; 38(7):77. PubMed ID: 34076777
[TBL] [Abstract][Full Text] [Related]
36. Design, Synthesis and Biological Evaluation of Novel HIF1α Inhibitors.
Masoud GN; Wang J; Chen J; Miller D; Li W
Anticancer Res; 2015 Jul; 35(7):3849-59. PubMed ID: 26124330
[TBL] [Abstract][Full Text] [Related]
37. HIF-1alpha and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides.
Lin J; Denmeade S; Carducci MA
Curr Cancer Drug Targets; 2009 Nov; 9(7):881-7. PubMed ID: 20025575
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of HIF-1α accumulation in prostate cancer cells is initiated during early stages of mammalian orthoreovirus infection.
Bussiere LD; Miller CL
Virology; 2021 Jun; 558():38-48. PubMed ID: 33721728
[TBL] [Abstract][Full Text] [Related]
39. Pentamidine is an inhibitor of PRL phosphatases with anticancer activity.
Pathak MK; Dhawan D; Lindner DJ; Borden EC; Farver C; Yi T
Mol Cancer Ther; 2002 Dec; 1(14):1255-64. PubMed ID: 12516958
[TBL] [Abstract][Full Text] [Related]
40. A protein therapeutic modality founded on molecular regulation.
Wright CM; Wright RC; Eshleman JR; Ostermeier M
Proc Natl Acad Sci U S A; 2011 Sep; 108(39):16206-11. PubMed ID: 21930952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
